Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

A multicenter, single-arm study of camrelizumab combined with rituximab followed by R-CHOP as first-line treatment for young patients with primary extranodal diffuse large B-cell lymphoma: The credit trial

View Full Paper
Ask AI
Bookmark
Share

Authors

YGYan GaoSun Yat-sen UniversityXZXuanye ZhangHebei Medical UniversityJHJi-Chen HongSun Yat-sen University

Discussion

Loading...

Member takes

Overview

Multicenter trial shows a 89.3% complete response in extranodal DLBCL patients treated with camrelizumab-R-CHOP, indicating effective frontline therapy.

Key Points

  • This research aims to evaluate the efficacy and safety of camrelizumab combined with rituximab followed by R-CHOP for primary extranodal DLBCL.
  • Conducted as a multicenter, prospective, single-arm trial.
  • Enrolled treatment-naïve patients aged 18-65 with histologically confirmed primary extranodal DLBCL.
  • Administered two cycles of camrelizumab and rituximab, followed by R-CHOP and maintenance camrelizumab for responders.
  • Primary endpoint was the complete response rate post-therapy according to Lugano criteria.
  • The overall complete response rate after camrelizumab-R-CHOP was 89.3% among evaluable patients.
  • At median follow-up of 23.9 months, progression-free survival was estimated at 86.8%.
  • Common treatment-emergent adverse events included leukopenia (56.6%) and neutropenia (53.3%).

Cite This Study

Gao et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d51fhttps://doi.org/10.1182/blood-2025-5517
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world efficacy and safety of pomalidomide-rituximab-based combination therapy in newly diagnosed extranodal diffuse large B-cell lymphoma2025
  2. 2Zilovertamab vedotin plus R-CHP versus R-CHOP for first-line treatment of diffuse large B-cell lymphoma: The phase 3 waveline-010 study2025 · 1 citations
  3. 3Rituximab, lenalidomide, and zanubrutinib (ZR2) with sequential CAR-T cell as first-line therapy for high-risk large B cell lymphoma2025
  4. 4Efficacy and prognosis of pola-R-CHP in CD5-positive DLBCL: Rapid response, long-term survival benefits, and early therapeutic optimization2025
  5. 5Intensified First Cycle of Rituximab Plus Eight Cycles of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab Chemotherapy for Advanced-Stage or Bulky Diffuse Large B-Cell Lymphoma: A Multicenter Phase II Consortium for Improving Survival of Lymphoma (CISL) Study2023 · 3 citations